Nurix Therapeutics, Inc. (NRIX) Earnings History
Profitable8 years of earnings data (2018–2025) · Positive TTM net income
Loading earnings history...
Nurix Therapeutics, Inc. (NRIX) Earnings Overview
As of November 8, 2026, Nurix Therapeutics, Inc. (NRIX) reported trailing twelve-month net income of $295M, reflecting -5.9% year-over-year growth. The company earned $2.54 per diluted share over the past four quarters, with a net profit margin of -314.9%.
Looking at the long-term picture, NRIX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2018.
Nurix Therapeutics, Inc. maintains positive profitability with a gross margin of 77.5%, operating margin of -340.2%, and net margin of -314.9%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including ARVN (-$10M net income, -30.8% margin), KYMR (-$349M net income, -794.4% margin), PRAX (-$339M net income), NRIX has room to improve margins relative to the peer group. Compare NRIX vs ARVN →
NRIX Earnings vs Peers
Earnings metrics vs comparable public companies
NRIX Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$264M | -36.6% | -$286M | $-3.05 | -314.9% | -340.2% |
| 2024 | -$194M | -34.5% | -$213M | $-2.88 | -354.9% | -390.5% |
| 2023 | -$144M | +20.2% | -$155M | $-2.65 | -187.0% | -201.4% |
| 2022 | -$180M | -53.9% | -$184M | $-3.71 | -466.9% | -476.0% |
| 2021 | -$117M | -171.0% | -$118M | $-2.73 | -393.9% | -396.3% |
| 2020 | -$43M | -99.3% | -$65M | $-2.76 | -242.7% | -364.7% |
| 2019 | -$22M | -130.2% | -$22M | $-0.56 | -69.7% | -71.5% |
| 2018 | -$9M | - | -$10M | $-0.59 | -25.2% | -26.0% |
Download Data
Export NRIX earnings history in CSV or JSON format
Free sign-in required to download data
NRIX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NRIX — Frequently Asked Questions
Quick answers to the most common questions about buying NRIX stock.
What is NRIX earnings per share (EPS)?
NRIX trailing twelve-month (TTM) diluted EPS is $2.54, reflecting -5.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Nurix Therapeutics, Inc.'s net income?
Nurix Therapeutics, Inc. (NRIX) trailing twelve-month net income is $295M as of 2025. Earnings declined -5.9% year-over-year.
Is NRIX profitable?
Yes, NRIX is profitable with a TTM net income of $295M and a net profit margin of -314.9%.
What is NRIX's earnings growth rate?
NRIX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are NRIX's profit margins?
Nurix Therapeutics, Inc. net profit margin is -314.9%, operating margin is -340.2%, and gross margin is +77.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -49.6%.
Is NRIX growing earnings?
NRIX earnings are declining — EPS fell -5.9% year-over-year. TTM net income dropped to $295M. This contrasts with the 5-year CAGR of N/A.
What was NRIX's best earnings year?
Nurix Therapeutics, Inc.'s highest annual net income on record is $-9M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were NRIX's earnings last quarter?
NRIX's most recent reported quarter was Q3 2026. Net income was $550M with diluted EPS of $4.73. For a full breakdown of all quarters, see the quarterly earnings table on this page.